Genetic Variants Identified from GWAS for Predisposition to Type 2 Diabetes Predict Sulfonylurea Drug Response


Journal Name: Current Molecular Medicine

Volume 17 , Issue 8 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Background: Several SNPs were identified through GWAS for their association with type 2 diabetes which has implications to pancreatic β-cell physiology.

Objective: We aimed to study the role of risk alleles of TCF7L2, KCNJ11, CDKN2A, CDKAL1, IGF2BP2, SLC30A8 and KCNQ1 along with pharmacokinetic variants in response to sulfonylureas.

Method: We performed a prospective study on 209 newly diagnosed subjects; treatment naive T2D subjects were recruited. Individuals were started with glibenclamide monotherapy and followed-up for 12 weeks. Genotyping was done, using PCR-RFLP and TETRA-ARMS PCR and confirmed by DNA sequencing.

Results: In univariate regression analysis, KCNJ11 (rs5219) was only the predictor for glibenclamide treatment failure.

Conclusion: The present data suggests a possible role of KCNJ11 gene in altered response to glibenclamide.

Keywords: Sulfonylurea, Glibenclamide, Genome Wide Association Studies (GWAS), Type 2 Diabetes, T-ARMSPCR, KCNJ11 gene.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 15 March, 2018
Page: [580 - 586]
Pages: 7
DOI: 10.2174/1566524018666180222122653
Price: $65

Article Metrics

PDF: 26
PRC: 1